Technological changes in the management of prostate cancer result in increased healthcare costs: A retrospective study in a defined Swedish population

Scandinavian Journal of Urology and Nephrology

Volumn 37, Issue 3, 2003, Pages 226-231

  Sennfält, Karin ^a,b   Carlsson, Per ^a   Thorfinn, Johan ^a   Frisk, Jessica ^a   Henriksson, Martin ^a   Varenhorst, Eberhard ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Costs; Prostate cancer; Technological changes

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ESTROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; DRUG COST; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HOSPITALS, COUNTY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROBABILITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SWEDEN; TECHNOLOGY, MEDICAL;

EID: 0038159416     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590310008109     Document Type: Article

References (18)

1. Cancerfonden, Socialstyrelsen. Cancer i siffror 1961-1996. Stockholm: 1999.
2. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer 2001; 92: 2796-810.
3. Sandblom G, Dufmats M, Nordenskjöld K, Varenhorst E. Prostate cancer trends in three counties in Sweden 1987-1996. Cancer 2000; 88: 1445-53.
4. Grover S, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal prostate cancer model. CMAJ 2000; 162: 987-92.
5. Carlsson P, Hjertberg H, Jönsson B, Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 1989; 23: 93-6.
6. Holmberg H, Carlsson P, Kalman D, Varenhorst E. Impact on health service costs of medical technologies used in management of prostatic cancer. Scand J Urol Nephrol 1998; 32: 195-9.
7. Cancerfonden, Socialstyrelsen. Cancer i siffror 2001. Stockholm: 2001.
8. Socialstyrelsen. Cancer incidence in Sweden 1999. Stockholm: Socialstyrelsen 2001.
9. Grover S, Zowall H, Coupal L, Krahn M. Prostate cancer: 12. The economic burden. CMAJ 1999; 160: 685-90.
10. Rothman KJ. Modern epidemiology. Little Brown: Boston, 1986.
11. Onkologiskt Centrum, Sydöstra Sjukvårdsregionen. Prostatacancer i Sydöstra Sjukvårdsregionen 2000, med redovisning av vårdprogramdata 1987-2000. Onkologiskt Centrum, Sydöstra Sjukvårdsregionen: Linköping, 2000.
12. Penson D, Schonfeld W, Flanders S, Henke C, Warolin K, Carroll P, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database. Urology 2001; 57: 499-503.
13. Littrup P. Future benefits and cost-effectiveness of prostate carcinoma screening. Cancer 1997; 80: 1864-74.
14. McNaughton Collins M, Ransohoff DF, Barry MJ. Early detection of prostate cancer. Serendipity strikes again. JAMA 1997; 278: 1516-9.
15. Adolfsson J, Marké L-Å. PSA use in Sweden. Proc Annual General Meeting of the Swedish Society of Medicine. Hygea: Stockholm, 2001: (in Swedish).
16. Rentzhog L, Hellström A-L, Kinn A-C, Lamnevik G, Lindehall B, Milsom I, et al. Evidence based treatment of urinary incontinence. Stockholm: The Swedish Council on Technology Assessment in Health Care, 2000: 143.
17. Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH. The Collection of Indirect and Non-medical Direct Costs (COIN) form: a new tool to collect the invisible costs of hormone-refractory prostate cancer. Cancer 2001; 91: 841-53.
18. Statistiska Centralbyrån. Statistisk Årsbok för Sverige 2001. Örebro, Sweden: Publikationstjänsten, 2001.